Regulation of TNF‐α and IFN‐γ induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive …
…, AM Bacon, K Carlson, AK Roshak… - The FASEB …, 2004 - Wiley Online Library
The chemokine CXCL10 is produced by many inflammatory cells found in the diseased lung
and has been implicated in the pathogenesis of chronic obstructive pulmonary disease (…
and has been implicated in the pathogenesis of chronic obstructive pulmonary disease (…
[HTML][HTML] Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS …
…, JC Curtin, N Haddish-Berhane, A Roshak… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)
exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …
exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
…, JC Curtin, RE Knoblauch, MV Lorenzi, A Roshak… - Cancer Discovery, 2020 - AACR
Currently, there are no approved targeted therapies for EGFR Exon20ins–driven NSCLC.
Preclinical data shown here, together with promising clinical activity in an ongoing phase I …
Preclinical data shown here, together with promising clinical activity in an ongoing phase I …
An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage
…, C Imburgia, JD Winkler, LA Marshall, A Roshak - Cancer research, 2000 - AACR
Many cancer therapies cause DNA damage to effectively kill proliferating tumor cells;
however, a major limitation of current therapies is the emergence of resistant tumors following …
however, a major limitation of current therapies is the emergence of resistant tumors following …
The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase
AK Roshak, EA Capper, C Imburgia, J Fornwald… - Cellular signalling, 2000 - Elsevier
Entry into mitosis by mammalian cells is triggered by the activation of the cdc2/cyclin B
holoenzyme. This is accomplished by the specific dephosphorylation of key residues by the …
holoenzyme. This is accomplished by the specific dephosphorylation of key residues by the …
Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl) amino]-5-(4 …
…, TG Davis, GW Mellor, C Evans, AK Roshak - … of Pharmacology and …, 2005 - ASPET
Demonstration that IκB kinase 2 (IKK-2) plays a pivotal role in the nuclear factor-κB-regulated
production of proinflammatory molecules by stimuli such as tumor necrosis factor (TNF)-α …
production of proinflammatory molecules by stimuli such as tumor necrosis factor (TNF)-α …
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC …
…, AR Minchom, JE Gomez, JC Curtin, G Gao, A Roshak… - 2021 - ascopubs.org
9006 Background: Preliminary efficacy was observed with the combination of amivantamab,
an EGFR-MET bispecific antibody, and lazertinib, a 3 rd -generation tyrosine kinase inhibitor…
an EGFR-MET bispecific antibody, and lazertinib, a 3 rd -generation tyrosine kinase inhibitor…
Small-molecule inhibitors of NF-κB for the treatment of inflammatory joint disease
AK Roshak, JF Callahan, SM Blake - Current opinion in pharmacology, 2002 - Elsevier
Recent advances in our understanding of the role of cytokine networks in inflammatory
processes have led to the development of novel biological agents for the treatment of chronic …
processes have led to the development of novel biological agents for the treatment of chronic …
The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore
CS Stevenson, EA Capper, AK Roshak… - … of Pharmacology and …, 2002 - ASPET
Marine natural products provide a rich source of chemical diversity that can be used to design
and develop new, potentially useful therapeutic agents. We report here that scytonemin, a …
and develop new, potentially useful therapeutic agents. We report here that scytonemin, a …
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer …
…, KH Lee, N Girard, PA Lorenzini, J Xie, A Roshak… - 2020 - ascopubs.org
9512 Background: EGFR exon20ins-mutated NSCLC is generally refractory to EGFR
tyrosine kinase inhibitors (TKIs) and is associated with poor prognosis. Amivantamab (JNJ-…
tyrosine kinase inhibitors (TKIs) and is associated with poor prognosis. Amivantamab (JNJ-…